Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2023.
Swedish Orphan Biovitrum (BIOVF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sobi plans to publish its report for the fourth quarter and full year of 2023 on 8 February 2024 at 08:00 CET.